KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2019)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $709000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $709000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $709000.0, a N/A change, with the full-year FY2019 number at $709000.0, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $709000.0 for Q4 2019 at Xenon Pharmaceuticals, up from $164000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $709000.0 in Q4 2019 to a low of $164000.0 in Q2 2015.